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ABSTRACT: We compared the performance of two 96-well multiplex immunoassay platforms in assessing plasma cytokine concentrations in
patients with glioblastoma (GBM; n = 27), individuals with melanoma, breast or lung cancer metastases to the brain (n = 17), and healthy volunteers (n = 11). Assays included a bead-based fluorescence MILLIPLEX® assay/Luminex (LMX) platform and 4 planar electrochemiluminescence
kits from Meso Scale Discovery (MSD). The LMX kit evaluated 21 cytokines and the 3 MSD kits evaluated 20 cytokines in total, with 19 overlapping human cytokines between platforms (GM-CSF, IFNγ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-17A, IL-21, IL-23, MIP1α, MIP-1β, MIP-3α, TNFα). The MSD platform had lower LLoQs (lower limits of quantification) than LMX for 17/19 cytokines, and higher LLoQs
for IFN-γ and IL-21. The ULoQs were higher in LMX versus MSD assays for 17/19 shared analytes, but lower than MSD for IL-17A and IL-21.
With LMX, all 19 shared analytes were quantifiable in each of 55 samples. Although MSD recombinant protein standard curves indicated lower
LLoQs than LMX for most cytokines, MSD detected 7/19 (37%) native analytes in <75% of samples, including 0% detection for IL-21 and 8%
for IL-23. The LMX platform categorized identical samples at greater concentrations than the MSD system for most analytes (MIP-1β the sole
exception), sometimes by orders of magnitude. This mismatched quantification paradigm was supported by Bland-Altman analysis. LMX identified significantly elevated levels of 10 of 19 circulating cytokines in GBM: GM-CSF, IFN-γ, IL-1β, IL-5, IL-10, IL-17A, IL-21, IL-23, MIP-1α, and
MIP-3α, consistent with prior findings and confirming the utility of applying appropriate multiplex immunoassay technologies toward developing
a cytokine signature profile for GBM.
Keywords: Chemokine, cytokine, glioblastoma multiforme, glioma, brain metastases, fluorescence, electrochemiluminescence, multiplex
immunoassay, in vitro assay, performance, precision, detection limit, lower limit of quantification, dynamic range
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Introduction

Gliomas are the most frequently diagnosed primary intracranial, intraparenchymal neoplasm.1 Glioblastoma (GBM), the
most common glioma histopathology (≈45% of all gliomas), is
an aggressive malignancy with a 5-year relative survival of only
≈5%, despite extensive ongoing research into surgical, chemotherapy, and radiological treatments. However, brain metastases from other primary sites are the most common intracranial
malignancies in adults, with an incidence of more than
170 000 per year in the US alone.2 By some estimates, more
than 40% of cancer patients develop brain metastases, including up to 50% of patients with lung cancer, >25% of patients
with breast cancer, and 20% of patients with melanoma.2
Cytokines and chemokines constitute a growing group of
small (<40 kDa) secreted bioactive proteins that perform
diverse interactive roles in molecular communication between
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cells and tissues.3,4 The balanced release of various cytokines is
important for maintaining normal homeostasis, and is also an
essential component of a well-regulated immune response that
changes in diverse disease states including cancers such as
GBM.5-7 Developing profiles of multiple interacting biomarkers in human plasma may have important utility in differentially diagnosing and staging both primary and secondary
intracranial tumors, tracking disease progression, estimating
prognosis, and selecting optimal management strategies and
following treatment responses.8-10
Multiplex immunoassays employ a variety of technologies,
including planar chemiluminescence and bead-based immunocapture suspension array platforms, to simultaneously quantify
circulating levels of many cytokines and other biomarkers.11
These approaches are useful for deciphering the complex
underlying biochemical mechanisms and interactions that
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occur during many disease states, have great possibilities for
accelerating epidemiological research, and are emerging as valuable clinical diagnostic and prognostic health appraisal tools.
This novel functionality is underscored by a progressive increase
in FDA approvals of multiplex proteomic assays for clinical
use.12 Multiplex immunoassays provide several advantages over
singleplex immunoassays for obtaining the same cumulative
information, including enhanced efficiency and reduced cost
when concurrently measuring multiple analytes from single
samples, increased throughput, and the mapping of complex
biochemical networks that may enable developing personalized
medical interventions.11,12 The relative benefits of multiplex
protein analysis over singleplex immunoassays are most obvious with scarce and valuable samples that are restricted in volume or accessibility, and when streamlining budget, workload,
and time expenditures are critical concerns.
Multiplex immunoassay platforms have distinct analytical
performance capabilities, strengths, shortcomings, and instrumentation and operator requirements. The current study compared the analytical performance characteristics of 2 different
commonly used multiplex platforms—a bead-based fluorescence assay and a planar chemiluminescence assay—to quantify circulating cytokine concentrations in human plasma
samples and to assess operator time requirements for assay
completion. Both methods employed 96-well microtiter plate
formats and measured 19 common cytokine analytes in identical samples. Additionally, we performed a time-and-motion
assessment of both operator-attentive and total time required
for assay completion with each method. Our group is interested in identifying and characterizing blood tumor biomarkers in brain cancer, and the evaluated plasma samples were
obtained from patients upon diagnosis of either primary glioblastoma or of brain metastases of various cancers originating
in other organs. Plasma samples from ostensibly healthy subjects were assessed as controls. The purpose of our study was to
interrogate multiplex methodologies to find the best platform
to comprehensively characterize circulating cytokine profiles
for oncological research, and to investigate their potential for
identifying molecular signatures specific for GBM and for
brain metastases from other primary sites.

Materials and Methods
Multiplex assay kits and instrumentation
This study compared 2 multiplex immunoassay detection systems. The bead-based fluorescence assay was the MILLIPLEX®
MAP Human High Sensitivity T Cell Magnetic Bead Panel
(Product #HSTCMAG28SMPX21; Merck EMD Millipore,
Billerica, MA), that simultaneously evaluates 21 analytes (fractalkine, GM-CSF, IFNγ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7,
IL-8, IL-10, IL-12p70, IL-13, IL-17A, IL-21, IL-23, ITAC,
MIP-1α, MIP-1β, MIP-3α, and TNFα) in suspension.13 This
assay was run on the Luminex® FLEXMAP 3D® detection
instrument operated with xPONENT Software V4.2 (both
from Luminex Corp., Austin, TX). This system has improved

sensitivity, broader dynamic range, and higher throughput than
the predecessor Luminex 100/200™ technology used in earlier
studies.11
The second platform was the electrochemiluminescencebased Meso Scale Discovery solid-matrix assay (MSD V-Plex®
kits; Meso Scale Discovery, LLC, Rockville, MD). Because
the MSD 96-well electrochemiluminescence immunoassay
kits that we used were limited to assessing 10 cytokines per
assay, we evaluated identical samples using 4 different kits, 3
customized, to achieve reasonable overlap with the 21-plex
LMX assay. The MSD Proinflammatory Panel 1 (Product
#K15049G) measures IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL 8,
IL-10, IL-12 (p70), IL-13 and TNF-α). We also purchased 3
customized kits that measured 3 to 4 relevant molecules each:
the TH17 V-Plex® (#K15085D) measured IL-21, IL-23, and
MIP-3α; the Cytokine Panel 1 (#K15050D) measured
GM-CSF, IL-5, IL-7, and IL-17A; and the Chemokine Panel
1 (#K15047D) measured IL-8 HA, MIP-1α, and MIP-1β.
The Quickplex SQ120 detection instrument was operated
using MSD Discovery workbench software v.3.0/4.0 (both
from Meso Scale Discovery).14 The Luminex/MILLIPLEX
and Meso Scale Discovery systems and associated results are
hereafter abbreviated as “LMX” and “MSD,” respectively.
Together, the LMX and MSD assays measured 19 common
cytokine analytes: GM-CSF, IFNγ, IL-1β, IL-2, IL-4, IL-5,
IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, IL-17A, IL-21,
IL-23, MIP-1α, MIP-1β, MIP-3α, and TNFα. Kits were used
before their stated expiration dates, and all assay steps were
performed in accordance with manufacturer instructions.13,14
With both platforms, samples and accompanying kit standards
were manually pipetted into assay plates. All samples were
assayed in duplicate in all kits. The LMX assay used 25 µL of
sample per duplicate well. The MSD kits used either 12.5 or
25 µL of sample per duplicate well, depending on the specific
kit. Thus, the LMX kit required 50 µL of each sample and the
MSD kits together required 150 µL of each sample to provide
desired analyte overlap. One key difference is the LMX assay
requires an overnight sample incubation time whereas the
MSD offers a standard 2-hour or alternative overnight sample
incubation. This experimental series used the manufacturerpreferred 2-hour incubation period for the MSD kits. Washing
steps for the LMX assay were performed using an automated
programmable washer-dispenser (BioTek MultiFlow FX reagent dispenser and BioTek 405 TS Microplate Washer (both
from BioTek, Winooski, VT). Reagents dispensation and plate
washing for the MSD assays were manually performed using a
multichannel pipettor.

Samples
Plasma samples were centrifugally separated from venous
blood samples drawn into EDTA-anticoagulant collection
tubes and stored at −80°C until analysis by both assays, having
undergone only a single freeze-thaw event. Demographic
information on sample donors is provided in Table 1. Subjects
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Table 1. Demographics of plasma donors.
Parameter

GBM

BrMet

HC

n

27

17

11

Gender, male/female, n

14/13

4/13

1/10

Age, y, mean ± SD

56.7 ± 12.7

59.0 ± 13.2

35.1 ± 7.8

Age, y, range

25-82

31-81

26-47

included 27 persons diagnosed with glioblastoma (GBM) and
17 persons with brain metastases (BrMet) from primary lung,
breast, or melanoma primary tumors. Plasma samples from 11
anonymous healthy control (HC) individuals were purchased
from Discovery Life Sciences (Los Osos, CA). This study was
performed under the approval and oversight of the Washington
University Institutional Review Board. All volunteers provided
written informed consent prior to enrollment and sample provision. Study performance complied with the tenets of the
Declaration of Helsinki.

Time and motion study

Experimental overview

Data were analyzed using Prism v.8 graphing and statistical
analysis software (GraphPad Software, Inc., San Diego, CA),
and Excel v.16 (Microsoft Inc. Redmond). Analyte concentrations were determined by comparing sample readings to standard curves generated using a 4-parameter logistical curve fit
algorithm (Belysa v.1 software from Millipore/Sigma for
LMX, and MSD Discovery v.3.0/4.0 for MSD. Analyte concentrations are presented as pg/mL ± SD, range, or as number
(% of samples), as appropriate. Means were compared by oneway ANOVA, followed by Tukey test for multiple comparisons.
Proportions of samples within the dynamic range were compared for each analyte using the Fisher Exact test. BlandAltman correlation plots show the mean ratios of MSD/LMX
concentrations detected for each analyte within each sample,
and include 95% limit-of-agreement representing mean values
±1.96 × SD. Any mean slope deviation from 1 was indicative
of proportional (concentration-dependent) bias in 1 or both
assays for that analyte.

Prior to analysis, all samples were thawed on ice and centrifuged at 15 000 × g for 10 minute at 4°C to remove potential
particulates. In all instances, samples were run in duplicate and
each assay plate contained recombinant standards for each analyte and quality control (QC) samples provided with the kits.
Calibration curves were established according to the user manuals using serial 4-fold dilutions of each kit’s stock analyte
standards. Blank values were established using the sample diluent supplied with each immunoassay kit. All samples were
diluted 1:2 or 1:4 using the sample diluent provided in each kit.

Assay performance characteristics
We assessed intra-assay precision, the lower and upper limits of
quantification (LLoQ and ULoQ, respectively), and the resulting dynamic ranges of cytokine detection for both assays.15,16
The mean of 8 blank values measured on LMX and MSD
plates were used to calculate the LLoQ, defined as the mean
blank signal + 2.5 × SD. The ULoQ was defined as the highest mean standard curve value for each analyte in each kit.

Comparative evaluation of cytokine levels in
human plasma
We measured the circulating concentrations of 19 cytokines
in diverse plasma samples from the 3 subject groups (GBM,
BrMet, HC) using both platforms, and evaluated whether values for any analyte were outside of the assays’ dynamic range of
quantification. Bland-Altman correlation plots were generated
to assess cytokine measurement agreement between LMX and
MSD.17

We evaluated and compared the precise time allocations
required for labor (operator hands-on and/or mandatory observation) and total times including incubations to evaluate a
similar number of analytes by both assay methods. All assays
were performed by the same technician. Observation and timing data collection were conducted by Nexus (Plano, TX), an
independent third-party healthcare consulting firm.

Data analysis

Results
Analytical limits of detection and quantification,
and dynamic range
The dynamic range was defined as the spread between the calculated LLoQ and the mean measured value of the highest
standard curve point (ULoQ), and was determined for all 22
analytes coordinately and individually measured by the LMX
and MSD systems. The dynamic ranges of quantification for
all 22 combined cytokine analytes that both assay platforms
measured are tabulated in Table 2, with the ranges of the 19
shared analytes shown graphically in Figure 1. Dynamic ranges
for all analytes in both assays were within the expected ranges
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Table 2. Limits of quantitation and dynamic range of analytes measured by the bead-based fluorescence (LMX) and planar
electrochemiluminescence (MSD) multiplex assays. Dynamic range spans the lower limit of quantitation (LLoQ) and upper limit of quantitation.
19 shared
analytes

LMX

MSD

Dynamic range
(pg/mL)

Dynamic range size
(fold of LLoQ)

Dynamic range
(pg/mL)

GM-CSF

0.90-18 629

20 699

0.05-4393

87 860

0.23

IFN-γ

0.19-9639

50 731

0.29-4745

16 362

3.10

IL-1β

0.21-7315

34 833

0.03-1791

59 700

0.58

IL-2

0.20-7633

38 165

0.07-5401

77 157

0.49

IL-4

1.49-28 992

19 458

0.01-761

76 100

0.26

IL-5

0.20-7581

37 905

0.08-3465

43 312

0.87

IL-6

0.66-2912

4412

0.04-2524

63 100

0.07

IL-7

3.62-5717

1579

0.06-3397

56 617

0.03

IL-8

0.10-4795

47 950

0.02-2277

113 850

0.42

IL-10

1.21-23 291

19 249

0.08-1806

22 575

0.85

IL-12 p70

0.27-7909

29 293

0.03-2217

73 900

0.40

IL-13

0.20-3913

19 565

0.11-1574

14 309

1.37

IL-17A

1.78-11 391

6399

0.23-20 872

90 748

0.07

IL-21

0.11-3818

34 709

0.22-5786

26 300

1.32

10 208

0.22-20 833

94 695

0.11

IL-23

12.15-124 034

MIP-1α

5.58-4604

MIP-1β

Dynamic range size
(fold of LLoQ)

Range size
ratio LMX/
MSD

825

1.17-4345

3714

0.22

0.57-14 808

25 979

0.30-3528

11 760

2.21

MIP-3α

0.60-9400

15 667

0.08-1806

22 575

0.69

TNF-α

0.08-6529

81 612

0.07-1362

19 457

4.19

Unshared
analytes

Dynamic range
(pg/mL)

Fractalkine

19.38-285 596

14 737

n/a

n/a

n/a

ITAC

1.58-22 425

14 193

n/a

n/a

n/a

IL-8 HA

n/a

n/a

109-239 574

Dynamic range
(pg/mL)

2198

‒

“n/a” indicates “not applicable” because that particular analyte was not included in the platform.

stated in assay lot-specific documentation. The MSD platform
had lower analytical LLoQs than LMX for 17 of 19 (89%)
shared cytokines. For IFN-γ, the LLoQ with LMX was 66% of
the MSD value, and for both IL-8 and IL-21, the LMX values
were 50% of LLoQs obtained using the MSD assay. The LMX
assay had higher ULoQs for 17 of 19 (89%) analytes, ranging
from 6% higher for MIP-1α to a maximal 3810% higher for
IL-4. In 2 analytes, IL-17A and IL-21, the ULoQs determined by LMX were 55% and 66% of the ULoQ measurements obtained with the MSD assay, respectively.
For 14 of 19 (74%) shared analytes, the MSD dynamic
range was larger than that of the LMX platforms; in the
remaining 5 instances (IFN-γ, IL-13, IL-21, MIP-1β, and
TNF-α), the LMX range breadth was between 32% and 419%

larger than the MSD range size (Table 2). Only in 2 analytes
(IL-5 and IL-10) were the LMX and MSD dynamic range
magnitudes within 20% of each other. In 2 instances (IL-4 and
IL-10), the differences in both upper and lower quantification
levels differed by at least an order of magnitude between the 2
assays.

Proportion of samples within assay quantification
range
A total of 55 plasma samples from all 3 experimental groups
were evaluated in duplicate wells using both platforms
(Figure 2). With the LMX system, all of the 19 shared
cytokines were quantifiable in 100% of samples tested. Despite

Bender et al
having a lower LLoQ for a plurality of common analytes, in
many instances the MSD chemiluminescence assay was unable
to detect these cytokines in human plasma samples. All
instances where experimental values fell outside of an analyte’s
dynamic range were with readings below the LLoQ; no value
ever exceeded the ULoQ for any analyte. The MSD platform
detected and quantified 7 of 19 analytes (37%) in 100% of samples (ie, IL-6, IL-7, IL-8, IL-10, MIP-1β, MIP-3α, and
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TNF-α). The MSD assay detection/quantification rate for
MIP-1α, IL-12p70, IL-1β, IL-17A, and IFN-γ in samples
was 96%, 90%, 86%, 76%, and 75%, respectively. The MSD
detection rate was <75% for the remaining 7 of 19 (37%) analytes, including a 0% detection rate for IL-21 and a 8% detection rate for IL-23. By contrast, the LMX system detected and
quantified valid concentrations of IL-21 (range 1.8-18.9 pg/
mL) and IL-23 (range 86.8-1922.2 pg/mL) in all samples.
Using Fisher Exact test, 11/19 analytes were missed at a significantly greater frequency in samples using MSD versus
LMX (Figure 2).

Analyte concentrations according to assay platform

Figure 1. Dynamic ranges of the Luminex bead-based fluorescence
(LMX) and Meso Scale Discovery electrochemiluminescence (MSD)
multiplex cytokine immunoassay kits. Ranges of quantification were
determined on standard calibration curves. With 3 exceptions (ie, IFN-γ,
IL-8, and IL-21), the low-end of the remaining 16/19 shared analytes’
dynamic ranges was lower with the MSD platform compared to the LMX
assay. Conversely, and with 2 exceptions (ie, IL-17A and IL-21), the
high-end of the dynamic range was greater with the LMX assay versus
the MSD assay. In 2 instances (IL-4 and IL-10), the differences in both
upper and lower quantification levels differed by at least an order of
magnitude between the 2 assays.

All 19 shared cytokine analytes were evaluated in 55 human
plasma samples comprising 27 glioma subjects, 17 subjects
with secondary brain metastases, and 11 controls (Figure 3 and
Table 3). The LMX platform categorized identical samples at
significantly greater concentrations than did the MSD system
for most analytes. Clear differences occurred with IL-4,
whereby LMX categorized cytokine concentrations at 4 orders
of magnitude higher than did MSD, and GM-CSF at 2 to 3
orders of magnitude greater than MSD values. Notably, when
the MSD platform evaluated IL-21, although the analyte
quantification limit on standard curves was 0.22 pg/mL, no
cytokine was detectable in any sample; the LMX platform,
however, returned values in all of the identical samples, ranging
from 1.8 to 18.9 pg/mL. Another prominent discrepancy
between assay detection performance occurred with IL-23,
which displayed a LLoQ that was 55-fold more sensitive with
MSD (0.22 pg/mL) than LMX (12.15 pg/mL). While IL-23
was quantifiable by LMX in 100% of samples, the MSD assay

Figure 2. Proportion of donor plasma samples inside the assay quantification range for the Luminex (LMX) and Meso Scale Discovery (MSD) multiplex
cytokine immunoassay kits. With the LMX system, all of the 19 shared cytokines were quantifiable in 100% of samples tested. Although the MSD assay
had a LLoQ below that of the LMX assay for 17/19 (89) common analytes in earlier standard curve performance evaluations, this sensitivity did not directly
translate to evaluating cytokines in human plasma samples. The MSD platform detected and quantified 7 of 19 analytes (37%) in 100% of plasma
samples. The MSD assay detection/quantification rate for MIP-1α, IL-12p70, IL-1β, IL-17A, and IFN-γ in samples was 96%, 90%, 86%, 76%, and 75%,
respectively. The MSD detection rate was <75% in the remaining 7 of 19 (37%) analytes, including a 0% detection rate for IL-21 and a 8% detection rate
for IL-23.

Asterisks indicate significant differences for 11/19 analytes between MSD and LMX by Fisher Exact test, with “*” indicating P < .05, “**” indicating P < .01, and “***”
indicating P < .001. No asterisk indicates mathematically similar detection frequencies between platforms for those cytokines.
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Figure 3. Cytokine concentrations in human plasma samples. All 19 shared cytokine analytes were evaluated in 55 human plasma samples comprising 27
glioma subjects, 17 subjects with secondary brain metastases (BrMet), and 11 healthy controls (HC). Values shown are mean concentration ± SD. The
Luminex (LMX) platform categorized identical samples at greater concentrations than the Meso Scale Discovery (MSD) system for most analytes. With IL-4,
wherein LMX categorized cytokine concentrations at 4 orders of magnitude higher than MSD, and GM-CSF values at 2-3 orders of magnitude greater than
MSD values. Notably, with IL-21, although the MSD lower quantification limit was 0.22 pg/mL, none was detectable by MSD in any sample. The LMX
platform identified IL-21 in all samples (range 1.8-18.9 pg/mL). With IL-23, the LLoQ was 55-fold more sensitive using MSD (0.22 pg/mL) than LMX (12.15 pg/
mL). While IL-23 was quantifiable by LMX in all samples, MSD detected the analyte in only 8% of samples, and categorized them at lower concentrations
(range 0.24-2.03 pg/mL) than LMX (range 86.8-1922.2 pg/mL). The MSD platform quantified 7 cytokines in 100% of samples (IL-6, IL-7, IL-8, IL-10, MIP-1β,
MIP-3α, and TNF-α), and expression trends of each of these across the 3 experimental groups were generally similar between MSD and LMX. With MSD,
IL-7 levels appeared lower in HC samples versus GBM and BrMet, which was not observed with LMX assessment. While IL-17A was detected in 100% of
samples by LMX and 76% by MSD, there a contradictory trend appeared in which IL-17 was lower in HC versus the 2 neoplasm groups with LMX, but higher
with MSD. Only MIP-1β levels were categorized as greater using MSD (range 16.06-166.88 pg/mL) versus LMX (range 4.26-19.65 pg/mL).
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Table 3. Cytokine levels measured by a bead-based fluorescence multiplex assay in plasma samples from healthy controls (HC; n = 11), subjects
with secondary brain metastases from other organs (BrMet; n = 17), and individuals with glioblastoma (GBM; n = 27).
Cytokine

HC Conc.
pg/mL ± SD

BrMet Conc.
pg/mL ± SD

GM-CSF

16.8 ± 5.1

31.6 ± 13.9

188

.011

31.2 ± 13.0

186

.008

IFN-γ

10.8 ± 3.5

17.5 ± 6.2

162

.037

20.0 ± 8.0

185

.0012

IL-1β

1.1 ± 0.4

2.1 ± 0.9

191

.026

2.6 ± 1.0

236

.0001

IL-2

4.7 ± 2.0

6.8 ± 2.8

145

4.8 ± 2.3

102

ns

IL-4

61.7 ± 16.2

111.1 ± 47.9

180

.003

66.9 ± 32.1

108

ns

IL-5

5.2 ± 1.6

11.5 ± 4.5

221

.005

13.0 ± 5.6

250

IL-6

7.3 ± 2.6

12.9 ± 6.3

178

.004

6.3 ± 2.6

86

ns

IL-7

18.0 ± 5.5

27.8 ± 6.8

154

<.001

17.6 ± 4.6

98

ns

IL-8

10.4 ± 5.6

12.7 ± 8.8

122

ns

7.3 ± 3.6

70

ns

IL-10

20.4 ± 10.8

69.7 ± 25.4

293

<.0001

71.2 ± 31.1

286

<.0001

4.1 ± 1.8

5.9 ± 2.2

143

ns

5.5 ± 1.9

134

ns

IL-13

10.3 ± 5.3

15.6 ± 7.4

151

7.1 ± 3.3

69

ns

IL-17A

12.1 ± 3.3

19.0 ± 7.4

157

19.3 ± 8.8

159

.028

IL-21

4.9 ± 2.9

10.1 ± 4.9

206

8.8 ± 3.9

180

.029

IL-23

356 ± 290

394 ± 171

111

792 ± 435

222

.004

MIP-1α

29.4 ± 3.9

40.2 ± 6.9

137

36.1 ± 7.7

123

.030

MIP-1β

8.4 ± 3.3

9.2 ± 4.1

109

ns

10.0 ± 3.7

119

MIP-3α

15.2 ± 9.1

14.9 ± 4.1

98

ns

20.8 ± 6.3

137

5.9 ± 2.3

4.2 ± 1.9

72

ns

6.0 ± 2.1

102

IL-12 p70

TNF-α

% of HC

P-value vs
HC

ns

.039
ns
.005
ns
.0008

GBM Conc.
pg/mL ± SD

% of HC

P-value
vs HC

.0002

ns
.045
ns

Concentrations are shown as mean pg/mL ± SD. P-values were determined by one-way ANOVA adjusted for multiple comparisons using Tukey test. Bolded values
indicate statistically significant differences from HC. Differences from HC that are not significant are labeled “ns”.

detected the analyte in only 8% of the same samples, and categorized them at a much lower concentration (range 0.352.03 pg/mL) than did LMX (range 86.8-1922.2 pg/mL).
Of the 7 analytes in which the MSD platform detected
quantifiable cytokine in 100% of samples (ie, IL-6, IL-7, IL-8,
IL-10, MIP-1β, MIP-3α, and TNF-α), the trends in relative
expression levels of these cytokines across the 3 experimental
groups were similar between MSD and LMX in most instances.
With MSD, values for IL-7 appeared lower in the HC samples
versus GBM and BrMet samples, which was not observed with
LMX assessment. With IL-17A, which was detected in 100%
of samples by LMX and 76% of samples by MSD, there
appeared to be a contradictory trend in which IL-17A was
lower in HC plasma versus the 2 neoplasm samples with LMX,
but higher with MSD. A similarly contrary relationship regarding IL-5 concentration in controls versus neoplasm groups was
observed.

In a single instance, MIP-1β, cytokine levels quantified by
MSD (range 16.06-166.88 pg/mL) were greater than concentrations determined by LMX (range 4.26-19.65 pg/mL), and
the relative expression level relationships across the 3 experimental groups appeared similar with both MSD and LMX.

Cytokine profiles in healthy, GBM, and BrMet
plasma
Because of the high frequency of non-quantifiable target
cytokines using the MSD platform, we limited our analysis of
patient versus HC to LMX findings, with which all analytes
were detectable in all samples, although MSD findings are provided in Supplemental Table 1. Concentrations of multiple
cytokines including GM-CSF, IFN-γ, IL-1β, IL-5, IL-10,
IL-17A, IL-21, IL-23, MIP-1α, and MIP-3α were significantly elevated in GBM plasma compared to HC (Table 3). Of
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these analytes, measured values were at least double in GBM
versus HC for 4, comprising IL-1β, IL-5, IL-10, and IL-23;
levels for GM-CSF (186%), IFN-γ (185%), and IL-21 (180%)
were very close to double in GBM versus HC plasma. Values of
cytokines measured in BrMet samples are shown in Figure 3
and Table 3. Cytokines that were commonly elevated in GBM
and BrMet plasma versus controls included GM-CSF, IFN-γ,
IL-1β, IL-5, IL-10, IL-21, and MIP-1α. Analytes that were
uniquely upregulated in GBM but not BrMet plasma included
IL-17. IL-23 and MIP-3α, all of which have inflammatory
functions and suspected roles in tumorigenesis.18-20 Analytes
that were uniquely elevated in BrMet but not GBM samples
compared to controls were the classical Th2 cytokines IL-4,
IL-6 and IL-13,21and IL-7, a promoter of both T- and B-cell
development.22 Interpretation of the significance of the various
analytes measured in BrMet plasma is confounded because
patients had received some type of chemotherapy regimen for
their non-brain primary tumor that likely affected cytokine
expression.

Correlation analysis
Correlations between LMX and MSD assay categorization of
levels of the 19 shared analytes measured in human plasma
were graphed on Bland-Altman plots (Figure 4).17 Log2 values
of the mean MSD/LMX analyte concentration ratios shown
on the y-axis estimates systematic bias. Good correlation is
assumed between assays if the mean value approximates zero
deviation. The 95% limits of agreement lines represent
±1.96 SDs from the mean. For most shared analytes, the mean
concentration ratio was shifted from zero to a positive value,
indicating that LMX classified the target cytokine in the same
plasma samples at a higher concentration than MSD. The sole
exception was with MIP-1β, where MSD characterized samples as containing markedly higher concentrations of cytokine
than LMX. Analyte-concentration-dependent effects (ie, proportional bias) were suggested by the slope of the mean line,
and were particularly notable for IL-7 and MIP-1β. The only
native cytokine whose concentration was characterized nearly
identically by both assays was IL-8. Interpretation of these data
becomes less certain when SDs are large and 95% limits of
agreement are spread further apart, reflective of widely distributed data points away from the mean. The maximum mean
differences were restricted to −200 or +200 due to software
limitations, but can theoretically be larger. In the case of IL-21,
no cytokine was identified within the MSD assay’s dynamic
range of quantitation in any sample; hence, the true mean difference is not 200, but infinity.

Time in motion study
Hands-on labor time was 1 hour 38 minutes for LMX and
2 hours 42 minutes for the MSD assays, reflecting the increased
number of MSD plates required. The total time required for

performing the single Luminex (LMX) 21-plex and 4 Meso
Scale Discovery (MSD) 3- to 10-plex assays was approximately
21.1 hours and 6.2 hours, respectively. This included a protocol-specified overnight primary antibody/sample incubation
for LMX, and a 2-hour primary antibody/sample incubation
for MSD (the alternative manufacturer-allowed overnight
incubation was not used).

Discussion

Cytokines are critical mediators of diverse disease states, and
have multiple pleotropic actions in different organs.3,4 Earlier
categorization of inflammatory and anti-inflammatory
cytokine categories has been revised with the appreciation that
cytokines function in complex interacting pathways, often
regulate the expression of other cytokines, and their inflammatory or anti-inflammatory roles depending upon their environmental context.23,24 Understanding the function of complex
cytokine networks in pathogenesis requires comparison of
expression profiles of multiple cytokines in health and disease
states.25 Cytokines can serve as molecular biomarkers that
provide insight into the development, progression, and prognosis of both acute health threats such as sepsis26 and trauma,27
and of chronic disorders including, for example, autoimmune,28
cardiopulmonary,29,30 and neoplastic diseases.5
Glioblastoma and brain metastases are particularly lethal
neoplastic disorders with limited treatment options,1,2 whose
pathogenesis may be modulated by multiple cytokines.6-10
Cytokines play important roles in immune cell infiltration and
function. Although the brain is generally an immunologically
specialized site, immune cell infiltration occurs in GBM tissue,
with macrophages/microglial cells comprising a significant
proportion of the tumor mass.31,32 We hypothesized that
cytokines released from the GBM or brain metastatic tissues,
and from immune cells in the tumor microenvironment, can be
non-invasively identified in the circulation. These unique
molecular profiles might provide information on disease existence, type, responsiveness to treatment, and prognosis. We
evaluated these hypothesized biomarker signatures using multiplex proteomic immunoassays.
Multiplex assays have advantages over classical singleplex
colorimetric ELISAs in that they simultaneously quantify
numerous bioactive molecules within a single small sample
volume to give a more complete overview of circulating
analytes.12,33,34 Multiplex immunoanalysis streamlines cytokine
profiling with improved productivity, while decreasing financial, time, and personnel expenditures needed to evaluate many
analytes individually.12,15,16 These benefits are particularly valuable when evaluating diverse cytokines in rare or size-limited
samples.
To identify potential circulating GBM-associated biomarkers, we compared concentrations of 19 cytokines in plasma from
newly-diagnosed GBM patients and healthy individuals, using
2 different multiplex immunoassay platforms.13,14 The dynamic
range of fluorescence and electrochemiluminescence multiplex
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Figure 4. Correlation analysis of concentrations of the 19 cytokines measured in 27 human plasma samples from patients with glioblastoma by the
Luminex (LMX) and Meso Scale Discovery (MSD) multiplex assays. Log2 values of MSD/LMX concentration ratios are shown on the y-axis, and estimate
systematic measurement differences between methods when the mean value deviates from zero. A negative shift of the blue mean indicates that the MSD
assay classifies the analyte at concentrations lower than LMX, and vice versa. The red ±1.96 SD lines represent 95% limits of agreement, and when SDs
are large or n-values are low, then interpretation can be ambiguous. For 17 of 19 shared analytes, the mean concentration ratio was shifted to a positive
value, indicating that LMX classified the target cytokine in identical plasma samples at a higher concentration than MSD. The sole exception was with
MIP-1β, where MSD characterized samples as containing markedly higher concentrations of cytokine than LMX. Analyte-concentration-dependent effects
were suggested by the slope of the mean line, and were notable for IL-7 and MIP-1β. The only cytokine similarly characterized by both assays was IL-8.

immunoassays is generally several orders of magnitude greater
than that of singleplex ELISAs.12,33,34 In our study, the MSD
platform calibration curves suggested superior sensitivity than
the LMX assay, with lower LLoQs for 89% of analytes, having
12 of 19 analytes’ LLoQ registering below 100 fg/mL. With
native proteins in plasma samples, however, the MSD assay was
surprisingly unable, in our hands, to detect or quantify many
cytokines that LMX assessed in the 1 to 100 pg/mL range. This

incongruous analyte classification was confirmed by correlation
analyses. An example of this disparity was IL-21, which LMX
quantified in all 55 of 55 samples (range 1.8-18.9 pg/mL) but
was not detected by MSD in any sample even though MSD
calibrator curves indicated a LLoQ of 0.22 pg/mL. Although
many parameters can affect multiplex immunoassay function,
we speculate that, while the MSD assay is excellent at quantifying the kit-specific recombinant cytokine fragments used for

10

calibration, it may be less efficient in detecting native proteins,
at least in the sample types/collection media we tested. While
this manuscript was in preparation, another publication reported
similar findings in which MSD missed detection of considerably more overlapping cytokine analytes in 62 (similarly EDTAanticoagulated) human plasma samples than simultaneously
performed LMX assays.35 Hands-on time required for LMX
assessment was only 60% of vigilant time required with MSD
because we needed to use 4 MSD plates to obtain desired analyte overlap with a single LMX 21-plex kit. Although assay
time determinations were only performed once per platform in
this study, our findings concur well with another report in which
hands-on labor time to assay 16 overlapping cytokines in human
plasma was reduced by 36% using LMX (1 hour 37 minutes)
compared to the MSD platform (2 hour 33 minutes).35 Given
the frequency of undetected analytes in samples with the MSD
platform, we focused on assessing results obtained using the
LMX assay.
Multiple cytokines were upregulated in the plasma of GBM
and/or BrMet subjects compared to circulating levels in healthy
volunteers. In GBM plasma, we identified significant elevation
of 10 of 19 evaluated cytokines versus control samples, comprising GM-CSF, IFN-γ, IL-1β, IL-5, IL-10, IL-17A, IL-21,
IL-23, MIP-1α, and MIP-3α. Of these analytes, measured
values were at least double in GBM versus HC for 4, comprising IL-1β, IL-5, IL-10, and IL-23; concentrations were nearly
double in GBM samples for GM-CSF, IFN-γ, and IL-21.
Cytokines that were commonly elevated in GBM and BrMet
plasma versus healthy control samples were GM-CSF, IFN-γ,
IL-1β, IL-5, IL-10, IL-21, and MIP-1α. Analytes uniquely
upregulated in GBM but not BrMet plasma included IL-17A,
IL-23, and MIP-3α, all of which have inflammatory activity
and are suspected to play proliferative and/or metastatic roles
in solid tumors including glioblastoma.18-20 Analytes uniquely
elevated in BrMet but not GBM plasma versus controls were
IL-4, IL-6, IL-7, IL-10, IL-13, and MIP-3α. Besides IL-5,
classical Th2 cytokines (ie, IL-4, IL-10, and IL 13) were notably elevated in BrMet but not GBM samples compared to
healthy control plasma. Cytokines that were commonly elevated in GBM and BrMet plasma versus controls included
GM-CSF, IFN-γ, IL-1β, IL-5, IL-10, IL-21, and MIP-1α.
Analytes that were uniquely upregulated in GBM but not
BrMet plasma included IL-17A and IL-23, both associated
with glioblastoma progression,18,19 and MIP-3α (chemokine
CCL20), which is an inflammatory chemokine with known
roles in solid tumor progression and metastasis.20 MIP-3α
contributes to the progression of liver, colon, breast, pancreatic,
and gastric cancers.36 In glioblastoma, MIP-3α released from
neighboring astrocytes may enhance malignancy by inducing
hypoxia-induced factor-1 (HIF-1) expression in tumor cells,
thereby promoting their survival and functionality in the
hypoxic tumor environment.37
Analytes that were uniquely elevated in BrMet but not
GBM samples compared to controls were the classical Th2
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cytokines IL-4, IL-6, and IL-13,21 and IL-7, a promoter of
both T- and B-cell development22 that is also a prognostic biomarker of improved survival in malignant glioblastoma.38
However, BrMet samples came from individuals who had variable histories of receiving chemotherapy for their primary nonbrain tumors, which can induce cytokine expression,39 thereby
confounding meaningful comparison with GBM findings. All
GBM samples were obtained at the time of initial diagnosis
from individuals who were treatment naïve, so cytokines differentially expressed in GBM plasma might be part of a valid
GBM-specific biomarker profile.
A similar study used bead-based immunoassays to profile
48 circulating cytokine levels, and identified an 18-cytokine
signature that discriminated 26 healthy subjects from 148
GBM patients with a diagnostic accuracy of 95.40%.40 Of the
18 markers detected by those researchers, 5 shared cytokines
were similarly upregulated in GBM in our study: GM-CSF,
IFN-γ, IL-12, IL-17A, and MIP-1α. When we queried the
US National Cancer Institute’s Cancer Genome Atlas
(TCGA) microarray database (available at https://portal.gdc.
cancer.gov/projects/TCGA-GBM), both GM-CSF and
IFN-γ showed increased transcript levels in GBM versus normal brain tissues, suggesting the tumor tissue itself as a primary source of these 2 circulating analytes. Conversely,
IL-17A was upregulated in GBM plasma by our protein analysis compared to control plasma, although transcript levels of
IL-17A were decreased in GBM tissue versus normal brain
tissue in the TCGA database. This suggests that cells extraneous to the primary tumor mass are responsible for the increased
circulating IL-17A that we detected in GBM plasma, but that
these biomarkers, together with others, might provide a
cytokine profile specific to GBM.
By univariate and multivariate cox regression survival
analyses, the earlier group determined that out of their identified 18-cytokine GBM signature, only IL-17A and IL-4
had good prognostic value.40 We identified a 1.7-fold
increase in plasma IL-17A levels in GBM versus healthy
subjects, but did not identify a difference in circulating IL-4
concentrations. Greater numbers of T helper type 17 (Th17)
cells in gliomas are associated with higher number of myeloid (CD11b) cells as well as the expression of TGF-β1 and
IL-6,41 though we saw no change in IL-6 and did not measure TGF-β1. IL-1β and IL-23, both of which we observed
to be elevated in GBM plasma, are critical in inducing the
Th17 phenotype in humans.42,43 Glioma-associated Th17
cells are potentially non-cytotoxic and may contribute to
immune suppression,41 and thereby disease progression.
Ultimately, the collective pattern of expression of these molecules might serve as a useful clinical biomarker signature
for detecting GBM and tracking progression. There may be
similar utility for cytokine signatures in patients with brain
metastases, although it is not surprising that the composition of cytokines detected may differ if systemic disease burden is variable.

Bender et al
Our findings support the discoveries of other researchers
toward identifying a GBM-specific circulating cytokine profile. Differences between our findings and those from a previous large cytokine profiling study40 may have resulted from
sampling differences, whereby we tested plasma from blood
collected in EDTA-anticoagulant solution and immediately
centrifuged then frozen, while the prior study collected sera
from whole blood specimens that were separated after allowing
sample coagulation overnight at 4°C before freezer storage.
Future studies will ascertain whether tightly-coordinated sampling and assay parameter selection can produce more congruity in establishing a definitive and prognostic GBM cytokine
biomarker signature. Additional work will be needed to determine how these cytokines change through the course of a
patient’s disease and whether cytokine expression in cerebrospinal fluid may also yield important insights. Future experiments should evaluate additional molecules with known or
suspected prognostic value in assessing GBM. It will be important to establish cytokine baselines at diagnosis, as reported
here, and then follow longitudinally how expression may
change throughout treatment, particularly with the increasing
interest in immunotherapy. Limitations of this study include
the relatively low number of GBM samples available for testing and the limited number of cytokines evaluated. We recognize that the complexities of multiplex proteomic immunoassay
procedures will require extensive validation before being
acceptable for clinical use. Ideally, all findings would be repeatable with the same samples using simplex immunoassays
employing the exact same reference cytokines used in the multiplex platform. Nonetheless, this study demonstrated that
appropriate multiplex platforms have important utility for dissecting the complex molecular mechanisms that drive the
pathology of diverse health disorders, including GBM and
metastatic cancers.
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